{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:18:35Z","timestamp":1792919915050,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. Of the patients, 30 (91%) achieved complete remission, and 3 (9%) achieved partial response. Within a median of 13 months, 10 patients (30%) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], \u03b22 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and\/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease. (Blood. 2004;104:1624-1630)<\/jats:p>","DOI":"10.1182\/blood-2003-12-4428","type":"journal-article","created":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T20:18:21Z","timestamp":1086639501000},"page":"1624-1630","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":216,"title":["Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma"],"prefix":"10.1182","volume":"104","author":[{"given":"Deborah A.","family":"Thomas","sequence":"first","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul S.","family":"Ha","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222270555600_REF1","doi-asserted-by":"crossref","unstructured":"Thomas D, Kantarjian H. Lymphoblastic lymphoma. In: Kantarjian H, Hoelzer D, Larson R, eds. Hematology\/Oncology Clinics of North America: Advances in the Treatment of Adult Leukemia, Part II. Vol 15. Philadelphia, PA: W.B. Saunders; 2001; 51-95.","DOI":"10.1016\/S0889-8588(05)70200-8"},{"key":"2020021222270555600_REF2","doi-asserted-by":"crossref","unstructured":"Coleman CN, Picozzi VJ, Cox RS, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol. 1986;4: 1628-1637.","DOI":"10.1200\/JCO.1986.4.11.1628"},{"key":"2020021222270555600_REF3","unstructured":"Picozzi VJ Jr, Coleman CN. Lymphoblastic lymphoma. Semin Oncol. 1990;17: 96-103."},{"key":"2020021222270555600_REF4","doi-asserted-by":"crossref","unstructured":"Quintanilla-Martinez L, Zukerbert L, Harris NL. Prethymic adult lymphoblastic lymphoma: a clinicopathologic and immunohistochemical analysis. Am J Surg Pathol. 1992;16: 1075-1084.","DOI":"10.1097\/00000478-199211000-00006"},{"key":"2020021222270555600_REF5","doi-asserted-by":"crossref","unstructured":"The non-Hodgkin's lymphoma pathological classification project: The National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Cancer. 1982;49: 2112-2135.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"2020021222270555600_REF6","doi-asserted-by":"crossref","unstructured":"Streuli RA, Kaneko Y, Variakojis D, et al. Lymphoblastic lymphoma in adults. Cancer. 1981;47: 2510-2516.","DOI":"10.1002\/1097-0142(19810515)47:10<2510::AID-CNCR2820471034>3.0.CO;2-8"},{"key":"2020021222270555600_REF7","doi-asserted-by":"crossref","unstructured":"Nathwani BN, Diamond LW, Winberg CD, et al. Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer. 1981;48: 2347-2357.","DOI":"10.1002\/1097-0142(19811201)48:11<2347::AID-CNCR2820481102>3.0.CO;2-X"},{"key":"2020021222270555600_REF8","doi-asserted-by":"crossref","unstructured":"Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer. 1999;85: 2648-2654.","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2648::AID-CNCR22>3.0.CO;2-R"},{"key":"2020021222270555600_REF9","doi-asserted-by":"crossref","unstructured":"Weiss LM, Bindl FM, Picozzi VJ, et al. Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood. 1986;67: 474-478.","DOI":"10.1182\/blood.V67.2.474.474"},{"key":"2020021222270555600_REF10","doi-asserted-by":"crossref","unstructured":"Catovsky D, Goldman JM, Okos A, et al. T-lymphoblastic leukemia: a distinct variant of acute leukemia. Br Med J. 1974;2: 643-646.","DOI":"10.1136\/bmj.2.5920.643"},{"key":"2020021222270555600_REF11","doi-asserted-by":"crossref","unstructured":"Bouabdallah L, Xerri L, Bardou VJ, et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol. 1998;9: 619-625.","DOI":"10.1023\/A:1008202808144"},{"key":"2020021222270555600_REF12","doi-asserted-by":"crossref","unstructured":"Morel P, Lepage E, Brice P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol. 1992;10: 1078-1085.","DOI":"10.1200\/JCO.1992.10.7.1078"},{"key":"2020021222270555600_REF13","doi-asserted-by":"crossref","unstructured":"Slater DE, Mertelsmann R, Koziner B, et al. Lymphoblastic lymphoma in adults. J Clin Oncol. 1986;4: 57-67.","DOI":"10.1200\/JCO.1986.4.1.57"},{"key":"2020021222270555600_REF14","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Bendandi M, Visani G, et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma. 1996;23: 577-582.","DOI":"10.3109\/10428199609054867"},{"key":"2020021222270555600_REF15","doi-asserted-by":"crossref","unstructured":"Bernasconi C, Brusamolino E, Lazzarino M, Morra E, Pagnucco G, Orlandi E. Lymphoblastic lymphoma in adult patients: clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphblastic leukemia. Ann Oncol. 1990;1: 141-146.","DOI":"10.1093\/oxfordjournals.annonc.a057692"},{"key":"2020021222270555600_REF16","unstructured":"Daenen S, van Imhoff GW, Haaxma-Reiche H, et al. Outcome of a hybrid chemotherapy regimen with mediastinal irradiation in leukemic T-lymphoblastic lymphoma [abstract]. Blood. 1995;86: 754a."},{"key":"2020021222270555600_REF17","doi-asserted-by":"crossref","unstructured":"Dekker AW, van't Veer MB, Sizoo W, et al. Intensive post-remission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia: Dutch Hemato-Oncology Research Group. J Clin Oncol. 1997;15: 476.","DOI":"10.1200\/JCO.1997.15.2.476"},{"key":"2020021222270555600_REF18","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Tobinai K, Shimoyama M, et al. Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross resistant chemotherapy: Japan Clinical Oncology Group Study 8702, Lymphoma Study Group. Jpn J Clin Oncol. 1999;29: 340-348.","DOI":"10.1093\/jjco\/29.7.340"},{"key":"2020021222270555600_REF19","doi-asserted-by":"crossref","unstructured":"Neth O, Seidemann K, Jansen P, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000;35: 20-27.","DOI":"10.1002\/1096-911X(200007)35:1<20::AID-MPO4>3.0.CO;2-L"},{"key":"2020021222270555600_REF20","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18: 547-561.","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"2020021222270555600_REF21","unstructured":"Thomas DA, Cortes J, Giles FJ, et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL) [abstract]. Blood. 2003;102: 880a."},{"key":"2020021222270555600_REF22","doi-asserted-by":"crossref","unstructured":"Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1: 292-293.","DOI":"10.1016\/S0140-6736(88)90367-4"},{"key":"2020021222270555600_REF23","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasma: a proposal from the International Lymphoma Study Group. Blood. 1994;84: 1361-1392.","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"2020021222270555600_REF24","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995;122: 254-261.","DOI":"10.7326\/0003-4819-122-4-199502150-00003"},{"key":"2020021222270555600_REF25","doi-asserted-by":"crossref","unstructured":"Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91: 3995-4019.","DOI":"10.1182\/blood.V91.11.3995"},{"key":"2020021222270555600_REF26","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31: 1860-1861."},{"key":"2020021222270555600_REF27","doi-asserted-by":"crossref","unstructured":"Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86: 2091-2097.","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091"},{"key":"2020021222270555600_REF28","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972;34; 187-220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2020021222270555600_REF29","unstructured":"Kaplan EL, Meier P. Non-parametric estimation form incomplete observations. J Am Stat Assoc. 1965;53: 457-481."},{"key":"2020021222270555600_REF30","doi-asserted-by":"crossref","unstructured":"Inhorn RC, Aster JC, Roach SA, et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia\/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995;85: 1881-1887.","DOI":"10.1182\/blood.V85.7.1881.bloodjournal8571881"},{"key":"2020021222270555600_REF31","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Go\u0308kbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002;99: 4379-4385.","DOI":"10.1182\/blood-2002-01-0110"},{"key":"2020021222270555600_REF32","doi-asserted-by":"crossref","unstructured":"Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer. 1980;45: 630-637.","DOI":"10.1002\/1097-0142(19800215)45:4<630::AID-CNCR2820450403>3.0.CO;2-5"},{"key":"2020021222270555600_REF33","doi-asserted-by":"crossref","unstructured":"Tubergen DG, Krailo MD, Meadows AT, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;13: 1368-1376.","DOI":"10.1200\/JCO.1995.13.6.1368"},{"key":"2020021222270555600_REF34","unstructured":"Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95: 416-421."},{"key":"2020021222270555600_REF35","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990;8: 994-1004.","DOI":"10.1200\/JCO.1990.8.6.994"},{"key":"2020021222270555600_REF36","doi-asserted-by":"crossref","unstructured":"Dabaja BS, Ha CS, Thomas DA, et al. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer. 2002;94: 2738-2744.","DOI":"10.1002\/cncr.10552"},{"key":"2020021222270555600_REF37","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Lepretre S, Briere J, et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87\/93 trials. Leukemia. 2003;17: 2220-2224.","DOI":"10.1038\/sj.leu.2403095"},{"key":"2020021222270555600_REF38","doi-asserted-by":"crossref","unstructured":"Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20: 205-213.","DOI":"10.1200\/JCO.20.1.205"},{"key":"2020021222270555600_REF39","doi-asserted-by":"crossref","unstructured":"Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18: 995-1003.","DOI":"10.1200\/JCO.2000.18.5.995"},{"key":"2020021222270555600_REF40","unstructured":"Thomas D, Kantarjan H, O'Brien S, et al. Outcome with the hyper-CVAD regimen in lymphoblastic lymphoma (LL) [abstract]. Proc Am Soc Clin Oncol. 1999;18: 11a."},{"key":"2020021222270555600_REF41","unstructured":"Thomas DA, Cortes J, O'Brien SM, et al. Improved outcome with the hyper-CVAD regimen in lymphoblastic lymphoma [abstract]. Blood2000;96: 833a."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/6\/1624\/1701602\/zh801804001624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/6\/1624\/1701602\/zh801804001624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:27:22Z","timestamp":1581546442000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/6\/1624\/18854\/Outcome-with-the-hyperCVAD-regimens-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,15]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-12-4428","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,15]]}}}